预约演示
更新于：2026-08-26
Pantoprazole Sodium Hydrate
泮托拉唑钠
更新于：2026-08-26
概要
基本信息
简介安托拉唑是一种小分子药物，被归类为质子泵抑制剂，这意味着它可以减少胃中产生的酸量。 Takeda Pharmaceutical Co., Ltd. 于 1994 年 1 月首次批准该药物。泮托拉唑在治疗消化性溃疡出血等疾病方面非常有效，消化性溃疡出血的特点是胃酸分泌过多，导致胃粘膜糜烂。当酸分泌会引起疼痛和出血时，它也可用于治疗禁食。一般来说，泮托拉唑耐受性良好且不良反应极小，使其成为酸相关疾病的常见治疗选择。 |
药物类型 小分子化药 |
别名 Anagastra、Controloc、Eupantol + [53] |
作用方式 抑制剂 |
作用机制 质子泵抑制剂 |
最高研发阶段批准上市 |
首次获批日期 德国 (1994-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C32H36F4N6Na2O11S2 |
InChIKeyZEPXBFIPCFSUOZ-UHFFFAOYSA-N |
CAS号164579-32-2 |
关联
300
项与 泮托拉唑钠 相关的临床试验NCT07683793
An Open-label, Fixed-sequence, Non-randomised, Drug-drug Interaction Study to Evaluate the Effect of Pantoprazole (Proton Pump Inhibitor) on the Pharmacokinetics of CHF10196 in Healthy Male Participants.
ChiCTR2600130206
Role of Sham Feeding with Chewing Gum in Managing Reduced Appetite, Nausea and Vomiting in Geriatric Patients Admitted at the Medical Ward
IRCT20260120068623N1
Comparison of the effect of a high-dose pantoprazole and amoxicillin (two medications) regimen to standard 4-drugs regimen in eradicating Helicobacter pylori infection in patients with dyspepsia or PUD
100 项与 泮托拉唑钠 相关的临床结果
登录后查看更多信息
100 项与 泮托拉唑钠 相关的转化医学
登录后查看更多信息
100 项与 泮托拉唑钠 相关的专利（医药）
登录后查看更多信息
6,509
项与 泮托拉唑钠 相关的文献（医药）2026-12-01IBRO Neuroscience Reports
Antiepileptic and antiepileptogenic effects of Lagenaria siceraria aqueous extract (Curcubitaceae) in PTZ-induced kindling in rats
Article
作者: Gnoupa, King-Ghislain Kenne ; Kom, Bibiane Tatiana Diebo ; Ngoufack, Stève Brunel Kenfack ; Diane, Ronel Bessam ; Foutsop, Aurelien Fossueh ; Noubouwo, Chirac Jospin ; Ngoupaye, Gwladys Temkou
Lagenaria siceraria (Curcubitaceae) is a plant traditionally used in Cameroon to treat epilepsy and other central nervous system disorders. The present study investigated the antiepileptogenic and antiepileptic effects of Lagenaria siceraria in PTZ-induced kindling in rats. Kindling was induced in male rats aged of 2-3 months using a challenging dose of PTZ (70 mg/kg, i.p.) followed by the administration of sub-convulsive doses of PTZ (35 mg/kg) every other day. The different treatments including the aqueous extract of Lagenaria siceraria (200 mg/kg and 400 mg/kg) were administered one hour before PTZ until the animals of negative group reached the kindled state. Seizure progression, latency of seizure and duration of seizure were assessed. After kindling was established, animals were sacrificed, hippocampus were collected to evaluate oxidative stress (malondialdehyde (MDA), reduced glutathione (GSH), catalase, nitric oxide (NO)), inhibitory neurotransmission (GABA, GABA-T), neuroinflammation (TNF-α, IL-1β), and blood-brain barrier integrity (MMP-9). The results showed that Lagenaria siceraria significantly increased the latency of seizure onset (***p < 0.001) and reduced seizure duration (***p < 0.001). Biochemically, Lagenaria siceraria significantly increased GABA and GSH levels and catalase activity (**p < 0.01), while GABA-T activity, TNF-α, IL-1β, MMP-9, MDA and NO levels were significantly reduced (*p < 0.05). Taken together, Lagenaria siceraria exhibited antiepileptic and antiepileptogenic effects by modulating GABAergic signaling, reducing oxidative stress and neuroinflammation. These findings support its traditional use and highlight its potential as an effective natural therapeutic agent for epilepsy.
2026-12-01MOLECULAR BIOLOGY REPORTS
The relationship of cucurbitacin E with epileptic seizures, circadian rhythm, and genetics in a pentylenetetrazole-induced mouse model of epilepsy
Article
作者: Sarıcı, Sinem Bebek ; Yılmaz, Şenay Görücü ; Ovayolu, Özlem
BACKGROUND:
Epilepsy is a chronic neurological disorder characterized by recurrent seizures resulting from abnormal neuronal electrical activity. Increasing evidence suggests that circadian clock dysfunction contributes to seizure susceptibility and neuronal excitability. Melatonin, a major regulator of circadian rhythm, possesses antioxidant and neuroprotective properties that may influence seizure regulation. Cucurbitacin E (CuE), a triterpenoid compound with potent antioxidant and anti-inflammatory activities, has emerged as a potential therapeutic agent targeting circadian and oxidative pathways. This study investigated the effects of CuE on seizure activity, oxidative balance, melatonin levels, and circadian clock gene expression in a pentylenetetrazol (PTZ)-induced epilepsy model.
METHODS:
Eighteen male C57BL/6 mice were randomly assigned to control, PTZ, and PTZ + CuE groups (baseline n = 6/group). PTZ (35 mg/kg/day, i.p.) was administered every other day for 12 days, while CuE (0.5 mg/kg/day, i.p.) was administered 30 min after PTZ injections. Two animals were excluded during the study, resulting in final group sizes of n = 6, n = 5, and n = 5, respectively. Seizure severity was assessed using Racine scoring, and locomotor activity was monitored using the LABORAS system with manual seizure validation. Serum melatonin, total antioxidant status (TAS), total oxidant status (TOS), and circadian clock gene expression (PER1, CRY1, CLOCK, BMAL1, RORA, and REV-ERBα) were analyzed.
RESULTS:
PTZ significantly increased seizure severity, oxidative stress, melatonin levels, and disrupted clock gene expression, whereas CuE markedly reduced seizures, improved oxidative balance, normalized melatonin levels, and partially restored circadian gene expression. Significant correlations were identified between melatonin levels and multiple clock genes.
CONCLUSION:
These findings demonstrate that CuE exerts anticonvulsant effects through integrated chronomodulatory and antioxidant mechanisms, supporting its potential as a multi-target therapeutic strategy for epilepsy management.
2026-12-01MOLECULAR BIOLOGY REPORTS
Proton pump inhibitor increases intestinal epithelial paracellular permeability via the p38-MAPK/NF-κB signaling pathway
Article
作者: Yu, Yan ; Cheng, Qiuyu ; Chen, Tao ; Liu, Wei ; Qian, Na ; Zhang, Xiaolei ; Qi, Junying ; Liu, Yunhui ; Zhang, Meng
BACKGROUND:
Proton pump inhibitors (PPIs), among the most widely administered medications globally, are correlated with adverse effects including fracture, enteric infections, gastroenteric tumors, and increased paracellular permeability of upper gastrointestinal tract. However, previous studies have primarily focused on PPI-induced intestinal microbiota dysbiosis or pH-dependent effects, the mechanisms underlying the association between PPI use and intestinal barrier dysfunction remain poorly understood. Therefore, this study aimed to investigate the relationship between PPI use and intestinal epithelial paracellular permeability both in vitro and in vivo, and to explore the potential signaling pathway mechanisms involved. These efforts seek to broaden the current understanding of the influence of PPIs therapy on intestinal barrier function.
METHODS AND RESULTS:
Different concentrations of pantoprazole sodium were administered intraperitoneally once a day for seven consecutive days in male C57BL/6J mice and were applied to Caco-2BBe cell monolayers accordingly. H&E was used to evaluate the epithelial morphology of jejunum and ileum. The permeability of FITC-dextran 4000 (FD4) and transepithelial electrical resistance (TEER) value were measured. The expression and distribution of occludin were assessed by quantitative real-time PCR, western blotting, and immunofluorescence analysis. The potential signaling pathways were also examined. PPI did not induce macroscopic lesions in the jejunum and ileum. However, PPI significantly decreased the mRNA and protein expression levels of occludin, reduced TEER values, and increased intestinal epithelial paracellular permeability of FD4 in the jejunum, ileum, and Caco-2BBe cell monolayers. In Caco-2BBe cell monolayers, the phosphorylation levels of p38-MAPK and NF-κB were higher in PPI-treated group than the control group. Pretreatment of Caco-2BBe cell monolayers with a p38-MAPK inhibitor (10 µM) prior to PPI exposure (100 µM) downregulated the activation of p38-MAPK and NF-κB, accompanied by increased occludin expression, elevated TEER value, and decreased FD4 permeability.
CONCLUSION:
Although the absence of macroscopic intestinal lesions, PPI directly enhances intestinal epithelial paracellular permeability by decreasing the expression of the tight junction protein occludin, mediated by the p38-MAPK/NF-κB signaling pathway. These findings highlight that the potential and insidious side effects of PPI on the intestinal epithelial barrier warrant increased attention and caution from clinicians when prescribing PPIs for various gastrointestinal diseases.
501
项与 泮托拉唑钠 相关的新闻（医药）2026-08-21
·普利制药
上市批准寡核苷酸
100 项与 泮托拉唑钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糜烂性食管炎 | 美国 | 2001-06-12 | |
| 胃食管反流 | 澳大利亚 | 1999-07-08 | |
| 幽门螺杆菌感染 | 澳大利亚 | 1999-07-08 | |
| 十二指肠溃疡 | 中国 | 1998-01-01 | |
| 反流性食管炎 | 中国 | 1998-01-01 | |
| 胃溃疡 | 中国 | 1998-01-01 | |
| Zollinger-Ellison综合征 | 中国 | 1998-01-01 | |
| 溃疡 | 德国 | - | 1994-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 消化性溃疡 | 申请上市 | 中国 | 2022-05-05 | |
| 消化性溃疡 | 申请上市 | 中国 | 2022-05-05 | |
| 出血 | 临床3期 | 中国 | 2018-04-24 | |
| 出血 | 临床3期 | 中国 | 2018-04-24 | |
| 上消化道出血 | 临床3期 | 中国 | 2015-11-13 | |
| 食管炎 | 临床3期 | 阿根廷 | 2006-05-01 | |
| 食管炎 | 临床3期 | 澳大利亚 | 2006-05-01 | |
| 食管炎 | 临床3期 | 奥地利 | 2006-05-01 | |
| 食管炎 | 临床3期 | 比利时 | 2006-05-01 | |
| 食管炎 | 临床3期 | 巴西 | 2006-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 76 | (Lansoprazole) | 積築襯網壓憲簾簾襯網(網淵獵淵構齋餘艱鏇衊) = 膚蓋糧廠積廠觸獵顧鏇 糧夢壓壓衊獵鹹餘範艱 (餘遞鏇淵膚顧齋鏇製願, 0.77) 更多 | - | 2026-06-04 | ||
(Pantoprazole) | 積築襯網壓憲簾簾襯網(網淵獵淵構齋餘艱鏇衊) = 淵廠憲網鹹獵淵糧築鏇 糧夢壓壓衊獵鹹餘範艱 (餘遞鏇淵膚顧齋鏇製願, 1.03) 更多 | ||||||
N/A | 48 | 願網範獵遞顧遞醖願鏇(蓋簾艱製遞鹽觸鬱顧餘) = Sucralfate was well tolerated, with no treatment-related adverse events 膚襯衊齋壓窪鹹鏇觸蓋 (獵淵餘廠顧積築窪鬱鬱 ) 更多 | 不佳 | 2026-05-27 | |||
N/A | - | 9,127 | 簾構鬱網製餘壓夢壓糧(範窪築顧觸淵襯網醖鹽): RR = 0.53 (95.0% CI, 0.29 ~ 0.94), P-Value = 0.03 更多 | 不佳 | 2026-05-02 | ||
Placebo | |||||||
临床2期 | 100 | (Famotidine Group) | 壓遞範憲遞鹽鹹積衊網(簾醖夢艱蓋構範糧壓遞) = 積夢齋夢獵膚憲憲鑰壓 艱餘繭觸衊鬱範窪膚醖 (廠膚觸廠願顧構繭觸衊, 顧鹹遞繭選範顧憲夢鑰 ~ 鏇壓簾願鹹顧膚鏇鏇鏇) 更多 | - | 2026-03-10 | ||
(Pantoprazole Group) | 壓遞範憲遞鹽鹹積衊網(簾醖夢艱蓋構範糧壓遞) = 觸憲製齋選築淵齋鬱鹹 艱餘繭觸衊鬱範窪膚醖 (廠膚觸廠願顧構繭觸衊, 鹽鑰願齋觸範廠簾衊鬱 ~ 積製網製壓夢鏇網鏇淵) 更多 | ||||||
临床3期 | - | 4,821 | 衊鑰顧蓋鹹積膚簾襯願(範壓衊窪夢淵窪壓膚襯) = 鹽憲網鹽簾壓醖鑰網鹹 餘憲蓋構鏇鬱簾獵糧淵 (構網糧衊鹹夢餘膚艱餘 ) 更多 | - | 2025-07-01 | ||
N/A | 301 | 鬱糧窪鏇繭憲艱鬱獵膚(鏇糧簾鏇憲鹹齋網蓋壓) = 廠廠獵積齋衊醖廠襯艱 憲淵醖膚鹽願窪蓋願憲 (襯壓齋製顧憲願顧蓋膚 ) 更多 | 不佳 | 2025-06-01 | |||
Normal saline | 鬱糧窪鏇繭憲艱鬱獵膚(鏇糧簾鏇憲鹹齋網蓋壓) = 鏇壓壓糧糧顧築鹽遞艱 憲淵醖膚鹽願窪蓋願憲 (襯壓齋製顧憲願顧蓋膚 ) 更多 | ||||||
N/A | 228 | Standard quadruple regimen at fixed doses | 製淵窪蓋壓衊網簾襯鹽(鏇鹽遞獵鹽願膚簾構壓) = 鹹製顧艱壓願鑰願製繭 顧範築壓鑰鬱窪膚鹽壓 (餘糧鏇鏇膚廠膚構鹹衊 ) 更多 | 积极 | 2025-05-03 | ||
higher doses of amoxicillin and metronidazole adjusted by body weight | 製淵窪蓋壓衊網簾襯鹽(鏇鹽遞獵鹽願膚簾構壓) = 願窪積糧淵築廠鏇糧觸 顧範築壓鑰鬱窪膚鹽壓 (餘糧鏇鏇膚廠膚構鹹衊 ) 更多 | ||||||
临床2/3期 | 60 | Placebo | 選窪衊簾鹹憲網觸鬱淵(襯鏇範積顧憲窪憲構製) = 餘願願積醖糧網顧範鹽 醖衊構遞獵遞淵衊膚鏇 (願襯鏇構製願築積艱鹽, 1.537) 更多 | - | 2024-09-23 | ||
临床3期 | 4,821 | 願網鹽製醖鬱鹽網顧衊(積範鹹壓遞憲積簾艱壓) = 觸網遞衊憲襯淵鹽憲積 觸獵醖鹽窪網膚獵壓淵 (襯窪艱鏇觸製繭網夢獵 ) | 积极 | 2024-07-04 | |||
Placebo | 願網鹽製醖鬱鹽網顧衊(積範鹹壓遞憲積簾艱壓) = 網遞襯艱願衊淵鏇獵糧 觸獵醖鹽窪網膚獵壓淵 (襯窪艱鏇觸製繭網夢獵 ) | ||||||
临床3期 | - | 膚獵鏇蓋遞積繭繭憲構(廠網糧壓淵簾憲壓繭鬱): OR = 0.89 (95% CI, 0.65 ~ 1.21) 更多 | 不佳 | 2024-07-01 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用